Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 24 Mar 2023 Acquisition of own shares Read More 18 Mar 2023 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks Read More 17 Mar 2023 Acquisition of own shares Read More 16 Mar 2023 UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis and Hidradenitis Suppurativa Read More 15 Mar 2023 Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease Read More 10 Mar 2023 Acquisition of own shares Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
